Condition: Ovary Cancer · Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
This description comes directly from the study's public registry record.
Hopkins GYN Trials · 410-614-1361 · HopkinsGynTrials@jhmi.edu
Sidney Kimmel Cancer Center Clinical Research Office · 410-955-8866 · jhcccro@jhmi.edu
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06617923